Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹218 cr of revenue in its latest quarter (Q1 FY27) and kept 6.4% of sales as profit.
Healthier than 35% of companies in Healthcare, on the 4 of 6 measures we could read for it. Each measure is ranked against the 37–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 58
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
Not measurable for this company: cash quality, growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in SYMBIOTEC?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-10-27.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹218 cr |
| Other Income | ₹33.8 L |
| Total Income | ₹218 cr |
| Cost of Materials | ₹103 cr |
| Purchases of Stock-in-Trade | ₹0 cr |
| Inventory Change (±) | ₹-27 cr |
| Employee Benefit Expense | ₹46 cr |
| Finance Costs | ₹6 cr |
| Depreciation & Amortisation | ₹22 cr |
| Other Expenses | ₹51 cr |
| Total Expenses | ₹201 cr |
| Profit before Tax | ₹18 cr |
| Tax Expense | ₹3 cr |
| Net Profit | ₹14 cr |
| Net margin on total income | 6.4% |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,740 | ₹4.17 L cr | 36.0 | 13.9% | 18.9% | — |
| Divi's Laboratories Limited | ₹9,050 | ₹2.40 L cr | 66.6 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,550 | ₹1.73 L cr | 81.0 | 11.6% | 10.7% | — |
| Zydus Lifesciences Limited | ₹1,160 | ₹1.16 L cr | 31.0 | 13.9% | 11.7% | — |
| Laurus Labs Limited | ₹2,059 | ₹1.11 L cr | 75.6 | 27.7% | 18.1% | — |
| Cipla Limited | ₹1,355 | ₹1.09 L cr | 34.7 | 9.2% | 11.1% | — |
| Dr. Reddy's Laboratories Limited | ₹1,311 | ₹1.09 L cr | 29.5 | 9.5% | 10.6% | — |
| Mankind Pharma Limited | ₹2,312 | ₹95,486 cr | 42.0 | 14.1% | 14.2% | — |
| Aurobindo Pharma Limited | ₹1,590 | ₹91,489 cr | 22.3 | 10.9% | 11.3% | — |
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.